Literature DB >> 23453100

Successive transradial access for coronary procedures: experience of Quebec Heart-Lung Institute.

Eltigani Abdelaal1, Pierre Molin, Guillaume Plourde, Jimmy Machaalany, Yoann Bataille, Cynthia Brousseau-Provencher, Sarah Montminy, Eric Larose, Louis Roy, Onil Gleeton, Gérald Barbeau, Can M Nguyen, Bernard Noël, Olivier Costerousse, Olivier F Bertrand.   

Abstract

BACKGROUND: Transradial approach (TRA) for cardiac catheterizations and interventions improves clinical outcomes compared with transfemoral access, and its use is increasing worldwide. However, there are limited data on successive use of same artery for repeat procedures.
METHODS: Between May 2010 and May 2011, all consecutive patients undergoing a repeat TRA procedure (≥2) were retrospectively identified. Success rates and reasons for failure to use ipsilateral radial artery for repeat access were identified.
RESULTS: A total of 519 patients underwent 1,420 procedures. In 480 patients (92%), right radial artery was used as initial access, and left radial artery, in 39 patients. All patients underwent ≥2 procedures; 218 patients, ≥3; 87 patients, ≥4; 39 patients, ≥5; 19 patients, ≥6; 11 patients, ≥7; and 5 patients, ≥8 procedures. Two patients had, respectively, 9 and 10 procedures. The success rate for second attempt was 93%, 81% for third, and declining to 60% for ≥8. Linear regression analysis estimated a 5% failure rate for each repeat attempt (R(2) = 0.87, P = .007). The main reason for failure was related to clinical radial artery occlusion (RAO) including absent or faint pulse, poor oximetry, and failed puncture. All patients with clinical RAO were asymptomatic. By multivariate analysis, female gender (odds ratio [OR] 3.08, 95% CI 1.78-5.39, P < .0001), prior coronary artery bypass graft (OR 5.26, 95% CI 2.67-10.42, P < .0001), and repeat radial access (OR 2.14, 95% CI 1.70-2.76, P < .0001) were independent predictors of radial access failure.
CONCLUSION: Successive TRA is both feasible and safe in most cases for up to 10 procedures. However, failure rate for TRA increases with successive procedures, primarily due to clinical RAO. Strategies to minimize the risks of chronic clinical RAO and allow repeat use of ipsilateral radial artery need to be further defined.
Copyright © 2013 Mosby, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23453100     DOI: 10.1016/j.ahj.2012.10.016

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  4 in total

Review 1.  Transradial Sheathless Approach for PCI.

Authors:  Douglas Fraser; Mamas A Mamas
Journal:  Curr Cardiol Rep       Date:  2015-06       Impact factor: 2.931

2.  Safe and rapid radial hemostasis achieved using a novel topical hemostatic patch: Results of a first-in-human pilot study using hydrophobically modified polysaccharide-chitosan.

Authors:  Rajeev Anchan; Joseph Venturini; Paul Larsen; Linda Lee; Christopher Fernandez; Stephanie A Besser; Rohan Kalathiya; Jonathan Paul; John Blair; Sandeep Nathan
Journal:  Catheter Cardiovasc Interv       Date:  2021-02-12       Impact factor: 2.585

3.  Impact of sheath size and hemostasis time on radial artery patency after transradial coronary angiography and intervention in Japanese and non-Japanese patients: A substudy from RAP and BEAT (Radial Artery Patency and Bleeding, Efficacy, Adverse evenT) randomized multicenter trial.

Authors:  Adel Aminian; Shigeru Saito; Akihiko Takahashi; Ivo Bernat; Robert Lee Jobe; Takashi Kajiya; Ian C Gilchrist; Yves Louvard; Ferdinand Kiemeneij; Niels van Royen; Maarten van Leeuwen; Seiji Yamazaki; Takashi Matsukage; Juan F Iglesias; Sunil V Rao
Journal:  Catheter Cardiovasc Interv       Date:  2018-02-16       Impact factor: 2.692

4.  Sheathless guiding catheter from a femoral approach for complex percutaneous coronary interventions -An unusual solution for an often-encountered problem.

Authors:  Zeev Israeli; Irina Nordkin; Alexander Goldberg; Majdi Halabi
Journal:  Clin Case Rep       Date:  2019-11-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.